COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

LORENZO ERRA; IGNACIO URIARTE; ANA COLADO; MARÍA VIRGINIA PAOLINI; GISELA SEMINARIO; JULIETA BELÉN FERNÁNDEZ; LORENA TAU; JULIANA BERNATOWIEZ; ILEANA MOREIRA; SEBASTIÁN VISHNOPOLSKA; MARTÍN RUMBO; CHIARA CASSARINO; GUSTAVO VIJODITZ; ANA LAURA LÓPEZ; RENATA CURCIARELLO; DIEGO RODRÍGUEZ; GASTÓN RIZZO; MALENA FERREYRA; LEILA ROMINA FERREYRA MUFARREGUE; MARÍA NOEL BADANO; MARÍA INÉS PÉREZ MILLÁN; MARÍA FLORENCIA QUIROGA; PATRICIA BARÉ; ITATÍ IBAÑEZ; ROBERTO POZNER; MERCEDES BORGE; GUILLERMO DOCENA; LILIANA BEZRODNIK; MARÍA BELÉN ALMEJUN

JOURNAL OF CLINICAL IMMUNOLOGY

SPRINGER/PLENUM PUBLISHERS

Lugar: New York; Año: 2022

0271-9142

Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfzer vaccines, even though most of the data of humoral and cellular responses combination on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the diferent vaccines in IEI patients in Argentina. The study cohort included adults and pediatric IEI patients (n=118) and age-matched healthy controls (HC) (n=37). B cell response was evaluated by measuring IgG anti-spike/receptor binding domain (S/RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T cell response was analyzed by IFN-γ secretion on S- or N-stimulated PBMC by ELISPOT and the frequency of S-specifc circulating T follicular-helper cells (TFH) was evaluated by fow cytometry. No moderate/severe vaccine-associated adverse events were observed. Anti-S/RBD titers showed signifcant diferences in both pediatric and adult IEI patients versus the age-matched HC cohort (p